Amelioration of hepatorenal syndrome with selective endothelin-A antagonist [20]

Lancet

Volumn 347, Issue 9018, 1996, Pages 1842-1843

  Soper, C P R ^a   Latif, A B ^a   Bending, M R ^a  

^a ST HELIER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN A RECEPTOR ANTAGONIST; CYCLO(TRP ASP PRO VAL LEU); CYCLO(TRP-ASP-PRO-VAL-LEU); CYCLOPEPTIDE; ENDOTHELIN;

ADULT; ALCOHOLISM; CASE REPORT; HEPATORENAL SYNDROME; HUMAN; LETTER; MALE; PRIORITY JOURNAL; DRUG ANTAGONISM; MIDDLE AGED;

ADULT; ALCOHOLISM; ENDOTHELINS; HEPATORENAL SYNDROME; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC;

EID: 0029786171     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)91667-0     Document Type: Letter

References (5)

1. R. Hecker S. Sherlock Electrolyte and circulatory changes in terminal liver failure Lancet ii 1956 1121 1125
2. S. Iwatsuki Mp Popovtzer Jl Corman Recovery from hepatorenal syndrome after orthotopic liver transplant N Engl J Med 289 1973 1155 1159
3. G. Laffi G. La Villa P. Gentilini Pathogenesis and management of hepatorenal syndrome 14 1994 New York: Thieme, Seminars in liver disease 71-81
4. K. Moore J. Wendon F. Marshall Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome N Engl J Med 327 1993 1774 1778
5. Tj Rabelink Kah Kaasjager P. Boer Effects of endothelin 1 on renal function in humans: implications for physiology and pathophysiology Kidney Int 46 1994 376 381